





Global Business Development & Licensing





Inspired by our values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society








Our business development activity takes many forms





with peer companies, biotechs and academia to enhance our portfolio and pipeline in our main therapy areas.



Out-licensing and divestment of medicines

that sit outside our main therapy areas and mature brands that can be deployed better by a partner. This allows us to maximise the value of our assets while ensuring patients have access to these medicines.



Joint research centres

with leading academic institutes across the globe.




Oncology scientific platforms

- New modalities & platform technologies
- Assets at all stages of R&D development
- Global & regional commercial partnerships

Tumour types







Therapeutic areas of interest in BioPharma

- New modalities & platform technologies
- Focus on clinical stage assets
- Commercial partnerships: global & regional









Cardiovascular

CV Disease

Heart Failure

Heart Failure with Reduced & Preserved **Ejection Fraction**



Renal

Chronic Kidney Disease, Acute Kidney Injury

Metabolism

Type 2 Diabetes, NASH



Respiratory

COPD Asthma Idiopathic **Pulmonary Fibrosis**



Respiratory

Chronic Cough



Immunology

SLE. Rheumatology, **Inflammatory Bowel** Disease




Dermatology

Atopic Dermatitis



More than 1,400 active collaborations in 2020





Our Partnering Teams Find out more: www.astrazeneca.com/partnering



BioPharmaceuticals BD & Licensing



Oncology BD & Licensing